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Abstract
A 27 year-old man who presented to the hospital with progressive lower extremity weakness,
developed an acute ST elevation myocardial infarction on his second hospital day. Primary
angioplasty to the left anterior descending coronary artery was performed. Due to persistent
dyspnea, the patient underwent a diagnostic chest computed tomography which confirmed multiple
small pulmonary emboli. Laboratory analysis revealed a megaloblastic anemia with a reduced
vitamin B12 level and positive titers for antibodies against intrinsic factor, establishing a diagnosis
of pernicious anemia. Screening for hypercoaguable markers documented an isolated severely
elevated homocysteine levels (105 μmol/l). No other significant risk factors for coronary artery
disease including a family history of premature atherosclerosis were identified. This case illustrates
the importance of testing for hyperhomocysteinemia as part of a workup for atherothrombotic
disease, especially in patients without other significant risk factors. The severity of
hyperhomocysteinemia found in our patient is unusual for patients with vitamin B12 malabsorption
and raises the question of whether the widely practiced folic acid fortification in the United States
may mask or even worsen vitamin B12 deficiency over time, leading to more severe cases of vitamin
B12 deficiency and hyperhomocysteinemia than seen in the past.
Background
Multiple epidemiological studies have demonstrated a
strong association between atherosclerotic vascular dis-
eases and hyperhomocysteinemia [1-3]. Levels of hyper-
homocysteinemia have been classified into mild-
moderate (homocysteine level, 16 to 30 μmol per liter),
intermediate (>31 to 100 μmol per liter), and severe
(>100 μmol per liter). Meta-analysis calculated an odds
ratio of 1.32 (95% confidence interval 1.19 to 1.45) for
the presence of ischemic heart disease with a 5 μmol/l
increase in serum homocysteine [4,5]. The independent
risk of cardiovascular events conferred by moderately ele-
vated serum homocysteine was the rational behind the
design for several recent prospective and randomized clin-
ical trials administering folic acid and B-vitamin supple-
mentations to lower serum homocysteine levels; all
studies to-date, however, have failed to achieve improved
vascular outcomes [6-10].
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While mild to moderately elevated homocysteine levels
are caused by a variety of factors including nutritional
deficiency of vitamin cofactors involved in the homo-
cysteine metabolism, severe elevation is generally only
observed in rare cases of genetic defects in the enzymes
which metabolize homocysteine. We present a young
man with an acute myocardial infarction due to a throm-
botic occlusion of the left anterior descending coronary
artery who also developed pulmonary emboli in the set-
ting of severe hyperhomocysteinemia secondary to perni-
cious anemia.
Case presentation
A 27 year-old male was admitted to the hospital with a
one month history of progressive and severe weakness,
numbness, and paresthesias of bilateral lower extremities.
The initial physical examination revealed normal vital
signs, an unremarkable cardiovascular examination and
disabling weakness in the lower extremities with impaired
vibratory sensation and absent reflexes in both ankles. On
his second day of hospitalization, the patient suddenly
developed crushing retrosternal chest pain, shortness of
breath and excessive diaphoresis. The patient was anxious,
tachypnic and his blood pressure at this time was 80/60
mmHg. An electrocardiogram (Figure 1) revealed anter-
oseptal ST-segments elevations with reciprocal changes
involving the inferior leads, consistent with an acute myo-
cardial infarction. A coronary angiogram (Figure 2) was
subsequently performed showing a large occluding
thrombus in the proximal left anterior descending artery
(LAD). The left circumflex and right coronary arteries were
patent without prominent luminal irregularities. The LAD
was successfully revascularized with percutaneous bal-
loon angioplasty with immediate improvement in the
patient's hemodynamics. The patient was started on aspi-
rin 325 mg daily, therapeutic unfractionated Heparin,
metoprolol and lisinopril. A transthoracic echocardio-
gram, completed the day after the intervention, revealed
hypokinesis of the apical anterior wall and mildly reduced
left ventricular function with an estimated ejection frac-
tion of 45%. The right ventricular size and function were
normal. Despite the successful coronary intervention, the
patient continued to experience dyspnea. Therefore, a hel-
ical computed tomography (CT)-scan of the chest was
performed which showed multiple small pulmonary
emboli to the left lower lung. Doppler ultrasound of the
lower extremities did not show deep venous thrombosis.
An extensive laboratory evaluation for his neuropathy as
well as hypercoagualble state revealed a mild anemia with
significant macrocytosis (hemoglobin 11.2 g/dl, mean
corpuscular volume 122 fl), hypersegmented neutrophils
(8.5%) and a high lactate dehydrogenase (LDH) (552 U/
L – Normal <180). Serum vitamin B12 blood levels were
Electrocardiogram: ST-elevations in lead V1–V4 and I and aVL with reciprocal ST-depression in the inferior leads III and aVF Figure 1
Electrocardiogram: ST-elevations in lead V1–V4 and I and aVL with reciprocal ST-depression in the inferior 
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low at158 pg/ml (Normal 197–894) with a normal serum
folate level of 12.1 ng/ml (Normal >3). Homocysteine
levels were severely elevated to105 μmol/l. Genetic testing
for the methylenetetrahydrofolate reductase C677T gene
mutation was negative. All other tests done to identify a
hypercoagulable state were normal as summarized in
Table 1. The patient tested positive for anti-intrinsic factor
antibodies (IFBA quantitative result of 6.61 arbitrary
units, Mayo Clinic, Rochester MN) which confirmed a
diagnosis of pernicious anemia; the patient was started on
daily intramuscular vitamin B12 injections. His lipid pro-
file was normal (total cholesterol of 139 mg/dl, LDL 51
mg/dl, HDL 40 mg/dl and triglycerides of 75 mg/dl).
A repeat transthoracic echocardiogram performed seven
days after the myocardial infarction showed persistent
anterior hypokinesis with normal left ventricular func-
tion. The right ventricular size and function were again
documented to be normal. After ten days of treatment
with vitamin B12 and folic acid supplements, homo-
cysteine levels normalized to 12.9 μmol/l. His neurologi-
cal symptoms gradually improved and the patient was
ultimately transferred to a physical therapy rehabilitation
facility with the following medical therapy: warfarin, vita-
min B12 s.c. supplementation, aspirin, metoprolol, lisi-
nopril and eplerenone.
Discussion
Kilmer McCully, the first pioneer to study the role of
hyperhomocysteinemia in the pathogenesis of arterioscle-
rosis, began by studying two children with two different
forms of hereditary enzymatic defects which led to severe
hyperhomocystenemia. Both these children presented
with significant vascular disease at very young ages. In
1969, McCully concluded that the vascular damage in
both cases was caused by an severely elevated homo-
cysteine level and he suggested a possible similar mecha-
nism in patients without genetic defects but who have
mild to moderately elevated homocysteine levels [11]. In
the years that followed, a large number of studies sup-
ported the presence of a strong association between ele-
vated homocysteine levels and various atherothrombotic
diseases including stroke, venous thromboembolism
(VTE) and ischemic cardiac disease [1-3]; a meta-analysis
of clinical observational studies consistently found that a
25 percent reduction in the serum homocysteine concen-
tration is associated with an 11 percent lower risk of
ischemic heart disease (odds ratio, 0.89; 95% confidence
interval, 0.83 to 0.96) and a 19 percent lower risk of stroke
(odds ratio, 0.81; 95% confidence interval, 0.69 to 0.95)
[5]. Furthermore, in vitro studies and animal models of
hyperhomocysteinemia have clearly shown multiple
mechanisms of homocysteine induced vascular dysfunc-
tion. Inhibition of endothelial cell nitric oxide produc-
Coronary angiogram showing a total occluded left anterior descending artery (LAD-T.O.) and a normal left circumflex coro- nary artery (LCX) Figure 2
Coronary angiogram showing a total occluded left anterior descending artery (LAD-T.O.) and a normal left 
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tion, enhanced oxidative stress, IL-8 up-regulation leading
to enhanced leukocyte recruitment, and up-regulation of
tissue factor within the vasculature are among many
mechanisms proposed underpinning homocysteine
induced cell injury [12-15]. However, lowering mildly ele-
vated homocysteine levels in patients with and without
vascular disease using vitamin supplementation did not
show a reduction in cardiovascular events in several pro-
spective and randomized clinical studies [7-10]. Possibly
harmful effects of vitamin therapy in certain settings have
been suggested in some trials. For example, the folate after
coronary intervention (FACIT) trial demonstrated that
administration of folic acid, vitamin B12 and vitamin B6
after coronary stenting might increase the risk of in-stent
restenosis and the need for target-vessel revascularization
[16].
In contrast to those studies which included patients with
mild to moderate elevations in homocysteine, our patient
had a severely elevated homocysteine level. Interestingly,
the etiology of the severity of hyperhomocysteinemia in
this case is not exactly clear as isolated vitamin B12 defi-
ciency due to pernicious anemia has not been reported to
directly cause such unusually high homocysteine levels
[17-19]. We did not identify other causes of hyperhomo-
cysteinemia and genetic testing for the common C677T
MTHFR gene mutation was negative. We realize the limi-
tation of testing for only one gene mutation, given that a
number of other genetic mutations in enzymes involved
in homocysteine metabolism can contribute to an eleva-
tion in plasma homocysteine levels [20]. However, the
absence of a family history for atherothrombotic diseases
together with the normalization of his homocysteine level
after only ten days of parenteral vitamin B12 supplemen-
tation strongly support that indeed vitamin B12 malab-
sorption secondary to pernicious anemia is the underlying
cause of his severe hyperhomocysteinemia. His normal
folate level likely may have contributed to the severity of
the homocysteine elevation by masking his megaloblastic
anemia, and leading to a later presentation of a more
severe neuropathy.
In fact, a recent study using data from the National Health
and Nutrition Survey (NHANES) between 1999–2002
found that participants with vitamin B12 deficiency and
high serum folate had increased homocysteine levels
compared to participants who had the combination of
vitamin B12 deficiency and low serum folate, suggesting a
Table 1: Summary of thrombophilia screening laboratory findings
Tests Results (Normal Range)
Prothrombin Time 10.6 seconds (8.9–11.7)
International Normalized Ratio (INR) 1 (0.8–1.3)
Activated Partial Thromboplastin Time 25.1 (24.5–35.2)
D-Dimer 6.79 mg/l (0.97–2.12)
Protein C activity (%) 110% (111–173)
Protein S activity (%) 118% (66–173)
Antithrombin III activity 110% (88–130)
Factor V Leiden mutation Negative
Prothrombin gene mutation Negative
Phospholipid (Cardiolipin) AB IgG Negative with <0.4 (norm <10.0)
Phospholipid (Cardiolipin) AB IgM Negative with <0.4 (norm <10.0)
Phospholipid (Cardiolipin) AB IgA Negative with <0.4 (norm <10.0)
Lupus Anticoagulant Absent
DNA doublestranded AB IgG Negative with <0.4 (norm <10.0)Thrombosis Journal 2009, 7:5 http://www.thrombosisjournal.com/content/7/1/5
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role of folate levels in vitamin B12's enzymatic functions
[21]. We speculate that his normal folate levels may have
contributed to the delay in diagnosing pernicious anemia
leading to severe hyperhomocysteinemia and the conse-
quent development of vascular injury and hypercoagua-
bility which presented as an acute myocardial infarction
and multiple pulmonary emboli.
Conclusion
This case clearly demonstrates that vitamin B12 deficiency
caused by pernicious anemia may lead to a severely ele-
vated homocysteine levels that can be rapidly corrected
with vitamin B12 supplements. Severe hyperhomo-
cysteinemia can be a risk factor for endothelial damage,
vascular inflammation and thrombus formation leading
to pulmonary emboli and in-situ coronary artery throm-
bus formation. We conclude that severe hyperhomo-
cysteinemia needs to be considered in the work-up of
acute myocardial infarction not explained by atheroscle-
rotic heart disease. Although studies have shown no pre-
ventive benefit from correcting mildly elevated
homocysteine levels, severe elevation in homocysteine
level should be corrected with appropriate vitamin ther-
apy to prevent vascular complications.
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